China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026)

China Pharma Holdings (CPHI) has reported Cost of Revenue for 17 consecutive years, with $864774.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 22.29% year-over-year to $864774.0; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (down 34.83% YoY), and the FY2025 full-year result was $4.3 million, down 34.36% from the prior year.
• Cost of Revenue climbed to $864774.0 in Q2 2026 per CPHI's latest filing, from $698049.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.9 million in Q4 2022 and bottomed at $698049.0 in Q1 2026.
• Historically, Cost of Revenue has averaged $1.6 million across 5 years, with a median of $1.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue surged 55.91% in 2024, then tumbled 49.63% in 2025.
• Over 5 years, Cost of Revenue stood at $2.9 million in 2022, then retreated by 22.56% to $2.2 million in 2023, then slumped by 41.92% to $1.3 million in 2024, then fell by 16.94% to $1.1 million in 2025, then declined by 19.57% to $864774.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $864774.0, $698049.0, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.